Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: Why they matter

Diabetologia

Volumn 56, Issue 6, 2013, Pages 1196-1200

  Valensi, P ^a   Chiheb, S ^a   Fysekidis, M ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Blood pressure; Cardiac autonomic neuropathy; GLP 1; Heart rate; Insulin; Obesity; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN;

AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; BODY MASS; HEART RATE; HEART RATE VARIABILITY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PULSE RATE; REVIEW; SYMPATHETIC TONE; VAGUS TONE;

FEMALE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; MALE; MYOCARDIUM; VAGUS NERVE;

EID: 84877749349     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2909-x     Document Type: Review

References (52)

1. Carnethon MR, Yan L, Greenland P et al (2008) Resting heart rate in middle age and diabetes development in older age. Diabetes Care 31:335-339
2. Stein PK, Barzilay JI, Domitrovich PP et al (2007) The relationship of heart rate and heart rate variability to non-diabetic fasting glucose levels and the metabolic syndrome: the Cardiovascular Health Study. Diabet Med 24:855-863
3. Palatini P (1999) Dynamic monitoring of blood pressure and assessment of antihypertensive drugs. Cardiologia 44(Suppl 1):1007-1010 [article in Italian]
4. Spallone V, Ziegler D, Freeman R et al (2011) Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 27:639-653
5. The Diabetes Control and Complications trial Research Group (1998) The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 41:416-423
6. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591
7. Valensi P, Thi BN, Lormeau B, Paries J, Attali JR (1995) Cardiac autonomic function in obese patients. Int J Obes Relat Metab Disord 19:113-118
8. Laitinen T, Lindstrom J, Eriksson J et al (2011) Cardiovascular autonomic dysfunction is associated with central obesity in persons with impaired glucose tolerance. Diabet Med 28:699-704
9. Valensi P, Extramiana F, Lange C et al (2011) Influence of blood glucose on heart rate and cardiac autonomic function. The DESIR study. Diabet Med 28:440-449
10. Valensi P, Paries J, Attali JR (2003) Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications - the French multicenter study. Metabolism 52:815-820
11. Liao D, Sloan RP, Cascio WE et al (1998) Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 21:2116-2122
12. Straznicky NE, Grima MT, Sari CI et al (2012) Neuroadrenergic dysfunction along the diabetes continuum: a comparative study in obese metabolic syndrome subjects. Diabetes 61:2506-2516
13. Maser RE, Lenhard MJ (2007) An overview of the effect of weight loss on cardiovascular autonomic function. Curr Diabetes Rev 3:204-211
14. Toyry JP, Niskanen LK, Mantysaari MJ et al (1997) Do high proinsulin and C-peptide levels play a role in autonomic nervous dysfunction? Power spectral analysis in patients with non-insulin-dependent diabetes and nondiabetic subjects. Circulation 96:1185-1191
15. Carnethon MR, Prineas RJ, Temprosa M, Zhang Z-M, Uwaifo G, Molitch ME (2006) The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care 29:914-919
16. de Jonge L, Moreira EA, Martin CK, Ravussin E (2010) Impact of 6-month caloric restriction on autonomic nervous system activity in healthy, overweight, individuals. Obesity (Silver Spring) 18:414-416
17. Straznicky NE, Eikelis N, Nestel PJ et al (2012) Baseline sympathetic nervous system activity predicts dietary weight loss in obese metabolic syndrome subjects. J Clin Endocrinol Metab 97:605-613
18. Bobbioni-Harsch E, Sztajzel J, Barthassat V et al (2005) The effect of insulin on cardiac autonomic balance predicts weight reduction after gastric bypass. Diabetologia 48:1258-1263
19. Valensi P, Paries J, Lormeau B, Attia S, Attali J-R (2005) Influence of nutrients on cardiac autonomic function in nondiabetic overweight subjects. Metabolism 54:1290-1296
20. Lindmark S, Lonn L, Wiklund U, Tufvesson M, Olsson T, Eriksson JW (2005) Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. Obes Res 13:717-728
21. Pop-Busui R, Evans GW, Gerstein HC et al (2010) Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 33:1578-1584
22. Valensi P, Doare L, Perret G, Germack R, Paries J, Mesangeau D (2003) Cardiovascular vagosympathetic activity in rats with ventromedial hypothalamic obesity. Obes Res 11:54-64
23. Cosson E, Herisse M, Laude D et al (2007) Aortic stiffness and pulse pressure amplification in Wistar-Kyoto and spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 292:2506-2512
24. Ayad F, Belhadj M, Paries J, Attali JR, Valensi P (2010) Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications. Diabet Med 27:804-811
25. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G (2000) Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 36:538-542
26. Grassi G, Dell'Oro R, Quarti-Trevano F et al (2005) Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48:1359-1365
27. Berkelaar M, Eekhoff EMW, Simonis-Bik AMC et al (2013) Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control. Diabetologia. doi: 10.1007/s00125-013-2848-6
28. van de Borne P, Hausberg M, Hoffman RP, Mark AL, Anderson EA (1999) Hyperinsulinemia produces cardiac vagal withdrawal and nonuniform sympathetic activation in normal subjects. Am J Physiol 276:178-183
29. Bellavere F, Cacciatori V, Moghetti P et al (1996) Acute effect of insulin on autonomic regulation of the cardiovascular system: a study by heart rate spectral analysis. Diabet Med 13:709-714
30. Vollenweider L, Tappy L, Owlya R, Jequier E, Nicod P, Scherrer U (1995) Insulin-induced sympathetic activation and vasodilation in skeletal muscle. Effects of insulin resistance in lean subjects. Diabetes 44:641-645
31. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L (1981) Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 30:219-225
32. Tack CJ, Lenders JW, Willemsen JJ et al (1998) Insulin stimulates epinephrine release under euglycemic conditions in humans. Metabolism 47:243-249
33. Paolisso G, Manzella D, Tagliamonte MR, Rizzo MR, Gambardella A, Varricchio M (1999) Effects of different insulin infusion rates on heart rate variability in lean and obese subjects. Metabolism 48:755-762
34. Morgan DA, Balon TW, Ginsberg BH, Mark AL (1993) Nonuniform regional sympathetic nerve responses to hyperinsulinemia in rats. Am J Physiol 264:423-427
35. Berne C, Fagius J, Pollare T, Hjemdahl P (1992) The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects. Diabetologia 35:873-879
36. Scherrer U, Sartori C (1997) Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 96:4104-4113
37. Paolisso G, Manzella D, Rizzo MR et al (2000) Effects of insulin on the cardiac autonomic nervous system in insulin-resistant states. Clin Sci (Lond) 98:129-136
38. Laitinen T, Vauhkonen IK, Niskanen LK et al (1999) Power spectral analysis of heart rate variability during hyperinsulinemia in nondiabetic offspring of type 2 diabetic patients: evidence for possible early autonomic dysfunction in insulin-resistant subjects. Diabetes 48:1295-1299
39. Valensi P, Smagghue O, Paries J, Velayoudon P, Lormeau B, Attali JR (2000) Impairment of skin vasoconstrictive response to sympathetic activation in obese patients: influence of rheological disorders. Metabolism 49:600-606
40. Tentolouris N, Tsigos C, Perea D et al (2003) Differential effects of high-fat and high-carbohydrate isoenergetic meals on cardiac autonomic nervous system activity in lean and obese women. Metabolism 52:1426-1432
41. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW (2000) Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 49:1525-1533
42. Kern W, Benedict C, Schultes B et al (2006) Low cerebrospinal fluid insulin levels in obese humans. Diabetologia 49:2790-2792
43. Anthony K, Reed LJ, Dunn JT et al (2006) Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 55:2986-2992
44. Tschritter O, Preissl H, Hennige AM et al (2006) The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A 103:12103-12108
45. Griffioen KJ, Wan R, Okun E et al (2011) GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res 89:72-78
46. Yamamoto H, Lee CE, Marcus JN et al (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110:43-52
47. Bharucha AE, Charkoudian N, Andrews CN et al (2008) Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 295:874-880
48. Russell-Jones D, Vaag A, Schmitz O et al (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52:2046-2055
49. Astrup A, Carraro R, Finer N et al (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36:843-854
50. Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 32:84-90
51. Wei Y, Mojsov S (1996) Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 157:355-357
52. Wahren J (2004) C-peptide: new findings and therapeutic implications in diabetes. Clin Physiol Funct Imaging 24:180-189